Neutrophilic asthma: a distinct target for treatment?

The Lancet Respiratory Medicine

Volumn 4, Issue 10, 2016, Pages 765-767

  Chung, Kian Fan ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CXCL1 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 5; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; N [2 (2,3 DIFLUOROBENZYLTHIO) 6 (2,3 DIHYDROXY 1 METHYLPROPOXY) 4 PYRIMIDINYL] 1 AZETIDINESULFONAMIDE;

ASTHMA; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; HUMAN; NEUTROPHILIC ASTHMA; NOTE; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT PLANNING; UNCONTROLLED PERSISTENT ASTHMA; INFLAMMATION; NEUTROPHIL;

ASTHMA; HUMANS; INFLAMMATION; NEUTROPHILS;

EID: 84989830298     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30232-6     Document Type: Note

References (16)

1. 1 Chung, KF, Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies. J Intern Med 279 (2016), 192–204.
2. 2 Macedo, P, Hew, M, Torrego, A, et al. Inflammatory biomarkers in airways of patients with severe asthma compared with non-severe asthma. Clin Exp Allergy 39 (2009), 1668–1676.
3. 3 Jatakanon, A, Uasuf, C, Maziak, W, Lim, S, Chung, KF, Barnes, PJ, Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 160 (1999), 1532–1539.
4. 4 Pavord, ID, Brightling, CE, Woltmann, G, Wardlaw, AJ, Non-eosinophilic corticosteroid unresponsive asthma. Lancet 353 (1999), 2213–2214.
5. 5 Fahy, JV, Kim, KW, Liu, J, Boushey, HA, Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol 95 (1995), 843–852.
6. 6 Manni, ML, Trudeau, JB, Scheller, EV, et al. The complex relationship between inflammation and lung function in severe asthma. Mucosal Immunol 7 (2014), 1186–1198.
7. 7 O'Byrne, PM, Metev, H, Puu, M, et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med, 2016 published online Aug 26. http://dx.doi.org/10.1016/S2213-2600(16)30227-2.
8. 8 Wenzel, SE, Barnes, PJ, Bleecker, ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 179 (2009), 549–558.
9. 9 Busse, WW, Holgate, S, Kerwin, E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 188 (2013), 1294–1302.
10. 10 Brusselle, GG, VanderStichele, C, Jordens, P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 68 (2013), 322–329.
11. 11 Hastie, AT, Moore, WC, Li, H, et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol 132 (2013), 72–80.
12. 12 Simpson, JL, Daly, J, Baines, KJ, et al. Airway dysbiosis: Haemophilus influenzae and Tropheryma in poorly controlled asthma. Eur Respir J 47 (2016), 792–800.
13. 13 Zhang, Q, Cox, M, Liang, Z, et al. Airway microbiota in severe asthma and relationship to asthma severity and phenotypes. PloS One, 11, 2016, e0152724.
14. 14 Bruijnzeel, PL, Uddin, M, Koenderman, L, Targeting neutrophilic inflammation in severe neutrophilic asthma: can we target the disease-relevant neutrophil phenotype?. J Leukoc Biol 98 (2015), 549–556.
15. 15 Saito, J, Zhang, Q, Hui, C, et al. Sputum hydrogen sulfide as a novel biomarker of obstructive neutrophilic asthma. J Allergy Clin Immunol 131 (2013), 232–234.
16. 16 Zhang, H, Gustafsson, M, Nestor, C, Chung, KF, Benson, M, Targeted omics and systems medicine: personalising care. Lancet Respir Med 2 (2014), 785–787.